The goal of asthma treatment is to avoid triggers and control airway inflammation.
- June 2010: Dulera (mometasone furoate/formoterol fumarate dehydrate; Merck) was FDA approved as treatment for asthma partially based on the results of two randomized clinical trials involving 1509 patients â‰¥12 years of age with persistent asthma uncontrolled on medium- or high-dose inhaled corticosteroids (ICS).
- August 2011: Verona Pharmaceuticals reported positive results from a phase II trial of RPL-554 for the treatment of mild asthma. RPL-554 is a novel, long-acting inhibitor of phosphodiesterase (PDE) 3 and PDE 4 enzymes, which combines bronchodilator and anti-inflammatory actions in a single drug.
- May 2012: Pulmatrix announced study results showing that iCALM (inhaled cationic airway lining modulator therapy) attenuated allergen-induced asthmatic bronchitis.